BackAltamira Therapeutics Ltd - Warrants (29/03/2028) Overview
Altamira Therapeutics Ltd - Warrants (29/03/2028)

Altamira Therapeutics Ltd - Warrants (29/03/2028) Return on Equity

Latest ROE for Altamira Therapeutics Ltd - Warrants (29/03/2028): -241.19% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

-241.19%

Return on Equity

-241.19%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Altamira Therapeutics Ltd - Warrants (29/03/2028) (CYTOW) FAQ

As of the most recent data, CYTOW shows a ROE of -241.19%. That is below the Healthcare sector average of 22.76%. Scroll down for historical charts and peer comparison views.

The Healthcare sector average ROE is about 22.76%. Altamira Therapeutics Ltd - Warrants (29/03/2028) is at -241.19%, which is lower that average. That is roughly 1159.5% below the sector mean. Use the comparison chart on this page to see how CYTOW stacks up against individual peers as well.

Check the historical chart to see whether CYTOW's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Altamira Therapeutics Ltd - Warrants (29/03/2028) with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has Altamira Therapeutics Ltd - Warrants (29/03/2028)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently -241.19%) with ownership activity and broader fundamentals.

The Healthcare average ROE is about 22.76%, while CYTOW is at -241.19%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.